← All trials
NCT03522129
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 16, 2018
- Primary completion
- Sep 30, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 18
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cognition TherapeuticsLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- Cognition TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.